Company intelligence / Profile preview

Hermes Innovations

San Carlos, California, United States

Ownership: Private
Development stage: Other

Overview

Hermes Innovations was a biotechnology company focused on the development of advanced pulmonary drug delivery systems. The company specialized in creating technologies that enabled the systemic delivery of large molecules, such as proteins and peptides, through inhalation. Its primary focus was on improving the delivery of insulin and other therapeutics for chronic conditions like diabetes and respiratory disorders. Hermes Innovations was acquired by Nektar Therapeutics (formerly Inhale Therapeutic Systems) in 2005 to bolster its portfolio of inhaled drug delivery technologies.

Therapeutic areas: EndocrinologyPulmonology
Modalities: Small moleculePeptidesProtein
Industry: Biotech

Partnerships

Nektar Therapeutics

Beyond the preview

Go deeper on Hermes Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hermes Innovations.

Explore the full profile